|By Marketwired .||
|May 19, 2014 07:00 AM EDT||
MOUNTAIN VIEW, CA--(Marketwired - May 19, 2014) - VIVUS (NASDAQ: VVUS) today announced that a poster describing results of a clinical study examining onset of action of avanafil will be presented during the American Urological Association Annual Meeting in Orlando, FL.
About the Presentation
Session Title: Sexual Function/Dysfunction/Andrology: Medical and Non-surgical
Abstract Number and Title: MP48-11 - Time to Erectogenic Effect of Avanafil in a Randomized, Placebo-Controlled Trial
Authors: Wayne J.G. Hellstrom, David Cook, LeRoy Jones, Charles H. Bowden, Wesley W. Day, Chien-Feng Chen
Date: Monday, May 19, 2014 - 8:00am -10:00am
Location: Orange County Convention Center - W314
STENDRA™ (avanafil) is approved by the FDA in the U.S. for the treatment of erectile dysfunction. STENDRA is rapidly absorbed and should be taken 30 minutes before sexual activity on an as-needed basis. STENDRA should not be taken more than once per day and may be taken without regard to food and with modest alcohol consumption.
VIVUS has granted Auxilium Pharmaceuticals, Inc. exclusive marketing rights to STENDRA in the U.S. and Canada; Auxilium is in the early stages of commercializing STENDRA in the U.S.
SPEDRA™, the trade name for avanafil in the European Union (EU), is approved by the European Medicines Agency (EMA) for the treatment of erectile dysfunction in the EU.
VIVUS has granted an exclusive license to the Menarini Group through its subsidiary Berlin-Chemie AG to commercialize and promote SPEDRA for the treatment of erectile dysfunction in over 40 European countries plus Australia and New Zealand.
VIVUS has granted an exclusive license to Sanofi to commercialize avanafil in Africa, the Middle East, Turkey, and the Commonwealth of Independent States (CIS) including Russia.
Avanafil is licensed from Mitsubishi Tanabe Pharma Corporation (MTPC). VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian-Pacific Rim countries. VIVUS is in discussions with other parties for the commercialization rights to its remaining territories.
For more information about STENDRA, please visit www.STENDRA.com.
Important Safety Information
STENDRA™ (avanafil) is prescribed to treat erectile dysfunction (ED).
Do not take STENDRA if you take nitrates, often prescribed for chest pain, as this may cause a sudden, unsafe drop in blood pressure.
Discuss your general health status with your healthcare provider to ensure that you are healthy enough to engage in sexual activity. If you experience chest pain, nausea, or any other discomforts during sex, seek immediate medical help.
STENDRA may affect the way other medicines work. Tell your healthcare provider if you take any of the following; medicines called HIV protease inhibitors, such as ritonavir (Norvir
In the rare event of an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.
In rare instances, men taking PDE5 inhibitors (oral erectile dysfunction medicines, including STENDRA) reported a sudden decrease or loss of vision. It is not possible to determine whether these events are related directly to these medicines or to other factors. If you experience sudden decrease or loss of vision, stop taking PDE5 inhibitors, including STENDRA, and call a doctor right away.
Sudden decrease or loss of hearing has been rarely reported in people taking PDE5 inhibitors, including STENDRA. It is not possible to determine whether these events are related directly to the PDE5 inhibitors or to other factors. If you experience sudden decrease or loss of hearing, stop taking STENDRA and contact a doctor right away. If you have prostate problems or high blood pressure for which you take medicines called alpha blockers or other anti-hypertensives, your doctor may start you on a lower dose of STENDRA.
Drinking too much alcohol when taking STENDRA may lead to headache, dizziness, and lower blood pressure.
STENDRA in combination with other treatments for ED is not recommended.
STENDRA does not protect against sexually transmitted diseases, including HIV.
The most common side effects of STENDRA are headache, flushing, runny nose and congestion.
Please see full patient prescribing information for STENDRA (50 mg, 100 mg, 200 mg) tablets.
VIVUS is a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity and sexual health. For more information about the company, please visit www.vivus.com.
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "predict," "opportunity" and "should," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS's Form 10-K for the year ended December 31, 2013, as amended by the Form 10-K/A filed on April 30, 2014, and periodic reports filed with the Securities and Exchange Commission.
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
Apr. 26, 2017 07:45 PM EDT Reads: 640
Apr. 26, 2017 07:15 PM EDT Reads: 9,053
Apr. 26, 2017 06:30 PM EDT Reads: 2,252
Apr. 26, 2017 06:30 PM EDT Reads: 3,696
Apr. 26, 2017 06:15 PM EDT Reads: 2,413
Apr. 26, 2017 06:15 PM EDT Reads: 2,220
Apr. 26, 2017 06:15 PM EDT Reads: 792
Apr. 26, 2017 05:45 PM EDT Reads: 677
Apr. 26, 2017 05:45 PM EDT Reads: 2,255
Apr. 26, 2017 05:30 PM EDT Reads: 2,152
Apr. 26, 2017 05:15 PM EDT Reads: 2,774
Apr. 26, 2017 05:00 PM EDT Reads: 916
Apr. 26, 2017 04:30 PM EDT Reads: 1,767
Apr. 26, 2017 04:15 PM EDT Reads: 556
Apr. 26, 2017 03:15 PM EDT Reads: 1,427